Eribulin drug has minor added benefit in one patient group, indication of lesser bene

[News]

Eribulin (trade name: Halaven) is approved for women with locally advanced or metastatic breast cancer in whom the disease has progressed despite prior drug therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups.

More... (http://www.news-medical.net/news/20141107/Eribulin-drug-has-minor-added-benefit-in-one-patient-group-indication-of-lesser-benefit-in-others.aspx)